Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Classement en actions #33640
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Prix de l'action
$0.03702159
Dernière synchronisation: 2024-01-29
Capitalisation boursière
$7.21M
Changement (1 jour)
-3.08%
Changement (1 an)
0.00%
Pays
AU
Échange Antisense Therapeutics Limited (ANP)

Catégorie

Ratio P/B pour Antisense Therapeutics Limited (ANP)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Antisense Therapeutics Limited, le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Antisense Therapeutics Limited de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes